	US 11,920,169 B2
	Compositions for linking DNA-binding domains and cleavage domains
Jeffrey C. Miller, Brisbane, CA (US); David Paschon, Brisbane, CA (US); and Edward J. Rebar, Brisbane, CA (US)
Assigned to Sangamo Therapeutics, Inc., Brisbane, CA (US)
Filed by Sangamo Therapeutics, Inc., Brisbane, CA (US)
Filed on Jun. 19, 2020, as Appl. No. 16/906,845.
Application 16/906,845 is a division of application No. 15/380,784, filed on Dec. 15, 2016, granted, now 10,724,020.
Claims priority of provisional application 62/290,065, filed on Feb. 2, 2016.
Prior Publication US 2020/0318087 A1, Oct. 8, 2020
Int. Cl. C12N 9/22 (2006.01); C12N 15/52 (2006.01); C12N 15/62 (2006.01); C12N 15/90 (2006.01)

CPC C12N 9/22 (2013.01) [C12N 15/52 (2013.01); C12N 15/62 (2013.01); C12N 15/907 (2013.01); C12Y 301/00 (2013.01); C07K 2319/00 (2013.01)]

34 Claims

1. A dimer comprising first and second fusion molecules, the first fusion molecule comprising a DNA binding domain that binds to a first target site and a first wild-type or engineered cleavage domain and the second fusion molecule comprising a DNA-binding domain that binds to a second target site and a second wild-type or engineered cleavage domain, wherein the first and second cleavage domains dimerize when the DNA-binding domains are bound to the first and second target sites separated by 7 base pairs, wherein the first fusion molecule comprises an amino acid linker between the DNA-binding domain and the first cleavage domain, wherein the linker is selected from the group consisting of:

	(SEQ ID NO: 114)
	SGERRQSHVL;

	(SEQ ID NO: 100)
	SGAIRCHDEFWF;

	(SEQ ID NO: 91)
	SGALQEPWSI;

	(SEQ ID NO: 138)
	SGFNHSSCDVVY;

	(SEQ ID NO: 147)
	QSGKIASPHVVI;

	(SEQ ID NO: 154)
	SGTPHEVGVYTL;

	(SEQ ID NO: 254)
	MGDEHRKLRLMSQMRLQVD;

	(SEQ ID NO: 255)
	KPRTDRKIFSLRLAN;

	(SEQ ID NO: 266)
	NPLPRNKYPSPYFLH;

	(SEQ ID NO: 267)
	APPAASKSRTWEMRR;

	(SEQ ID NO: 268)
	LNRPKLNTRPHYTSV;
	and

	(SEQ ID NO: 269)
	QTRPPRSFCMLAMTG.